Posted March 4, 2021
On Jan. 20, the Biden administration named Dr. Janet Woodcock acting commissioner of the U.S. Food and Drug Administration (FDA). As The New York Times reported over the weekend, Woodcock is “one of two leading contenders” to lead the agency, but she faces “strong opposition.” Among those opposing Woodcock’s appointment as FDA commissioner is as a coalition of nonprofit advocacy groups who argue that Woodcock’s “inadequate” oversight of the FDA during the opioid crisis should disqualify her. Read more.